Clinical trials: Systemic Lupus
Systemic Lupus Erythematosus, CAR-T Cell Therapy
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
This is an investigator-initiated trial aimed at assessing the safety of anti-CD19 CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT06222853
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Study During Pregnancy of Expression of miRNAs in RA or SLE
Rheumatoid arthritis (RA) is a systemic disease, which mainly targets joints and results in osteoarticular destruction and serious disability.
- Trial name
- SPIRALE (NCT02350491)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Systemic Lupus Erythematosus
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
Accelerated atherosclerosis is an established complication of systemic autoimmune diseases, particularly SLE. Young female patients with SLE are more likely to develop myocardial infarction than matched healthy controls, and CVD…
- Trial name
- ISLE (NCT04276701)
- Testing
- blood sample, Ultrasonography assessment, questionnaires
- Where
- 6 sites in France, Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital, Bordeaux
Safety, Effective
Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This is an open, Phase I, investigator-initiated study (IIT) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with moderate or severe active SLE.
- Trial name
- NCT06310811
- Testing
- RD06-04 Cells injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus, Systemic Sclerosis
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
This is an open-label, investigator-initiated clinical trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with active SLE, SSc, AAV, IIM, and pSS
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06549296
- Testing
- RD06-04 CART Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
SLE (Systemic Lupus), Chronic Pain
A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic Pain
This research will assess the feasibility of a tailored yoga coaching program for reducing pain-related symptoms among people with systemic lupus erythematosus.
- Trial name
- MiPAL (NCT07196072)
- Testing
- MiPAL
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erythematosus
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
- Trial name
- NCT07318259
- Testing
- BCMA/CD70 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus, Telitacicept
A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.
The objective of this observational study is to compare the efficacy and safety of tixocutibine and belizumab in the treatment of systemic lupus erythematosus in patients aged 18-65 years with systemic lupus erythematosus.
- Conditions
- Systemic Lupus Erythematosus, Telitacicept, Belimumab, Efficacy and Safety
- Trial name
- NCT07053137
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Yipeng Liu
Systemic Lupus Erythematosus
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
The objective of this observational study is to compare the efficacy and safety of telitacicept versus belimumab in systemic lupus erythematosus (SLE) patients aged 18-65 years.
- Trial name
- NCT07069972
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Yipeng Liu
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.
- Trial name
- NCT07331272
- Testing
- LUCAR-G79D T cells
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Nanjing Legend Biotech Co.
Lupus Erythematosus, Systemic
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE).
- Trial name
- TOPAZ-2 (NCT04961567)
- Testing
- Litifilimab
- Where
- 177 sites in United States, Argentina and 15 more
- Volunteers
- 562 people
- Sponsor
- Biogen
Lupus, Lupus Arthritis
The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study
This study aims to capture the Canadian patient experience, burden, barriers, and treatment preferences. The findings will generate real-world evidence to support patient-centered care and guide healthcare providers, researchers…
- Conditions
- Lupus, Lupus Arthritis, Lupus Arthritis, Systemic Lupus Erythematosus, Quality of Life (QOL)
- Trial name
- NCT07267091
- Testing
- No Intervention: Observational Cohort
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- PeriPharm
Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV)
IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
This is an exploratory trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of a single dose of IMPT-514, an autologous, anti-CD19/CD20 CAR T therapy, administered as an intravenous (IV)…
- Conditions
- Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)
- Trial name
- NCT06462144
- Testing
- IMPT-514 CART Cell Injection
- Where
- 3 sites in China
- Volunteers
- 3 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
The primary objective of this phase Ib study is to evaluate the safety and tolerability of multiple-ascending, subcutaneous (SC) doses of HC022 in SLE/CLE subjects.
- Trial name
- NCT07306585
- Testing
- HC022
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HC Biopharma Inc.
Lupus or SLE, Interstitial Lung Disease
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and…
- Conditions
- Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
- Trial name
- NCT07077486
- Testing
- Methylprednisolone (Corticosteroid), Immunosuppressant other than CYC, Telitacicept Freeze-dried powder Injection 80mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Research Accelerated by You Lupus Registry
Summary The Lupus Foundation of America (LFA) Research Accelerated by You (RAY) Registry is a fully remote, longitudinal registry designed to collect data from adults and children living with lupus.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
- Trial name
- RAY (NCT06927219)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Lupus Foundation of America
Systemic Lupus Erythematosus, Lupus Nephritis
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
This is an open-label investigator-initiated trial (IIT) to assess the safety, efficacy, and PK（pharmacokinetic）/PD（pharmacodynamics ） of UB-VV410 in adult subjects with clinically active treatment-refractory SLE.
- Trial name
- NCT07109986
- Testing
- UB-VV410
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
Lupus Nephritis, Lupus Nephritis (LN)
Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus
The purpose of this clinical trial is to evaluate the safety and efficacy of CRC01, an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, in people with lupus nephritis (LN), a serious kidney…
- Conditions
- Lupus Nephritis, Lupus Nephritis (LN), SLE, SLE (Systemic Lupus)
- Trial name
- CRC01-02 (NCT07364396)
- Testing
- CRC01
- Volunteers
- 39 people
- Sponsor
- Curocell Inc.
Systemic Lupus Erythematosus
Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates…
- Trial name
- NCT04971590
- Testing
- Participant completed survey, Medical chart review
- Where
- 6 sites in Kuwait, Oman and 2 more
- Volunteers
- 193 people
- Sponsor
- GlaxoSmithKline